References
- The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329(14): 977–86
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352(9131): 837–53
- Bliss M. The discovery of insulin. Chicago: University of Chicago Press, 1982: 112–3
- White JR Jr, Campbell RK, Hirsch I. Insulin analogues: new agents for improving glycemic control. Postgrad Med 1997; 101(2): 58–70
- Setter S, White J, Campbell RK. Diabetes mellitus. In: Herfindal T, Gourley D, eds. Textbook of therapeutics: drug and disease management. 7th ed. Philadelphia: Lippincott Williams & Wilkins, 2000: 377–406
- Brange J, Owens DR, Kang S, et al. Monomeric insulins and their experimental and clinical implications. Diabetes Care 1990; 13(9): 923–54
- Scholtz HE, et al. (Abstr) Diabetologie 1999; 42(Supp1 1): A235
- Campbell RK, White JR Jr. Insulin therapy in type 2 diabetes. J Am Pharm Assoc (Wash) 2002; 42(4): 602–11
- Roach P, Yue L, Arora V. Improved postprandial glycemic control with Humalog Mix25, a novel protamine-based insulin lispro formulation. Humalog Mix25 Study Group. Diabetes Care 1999; 22(8): 1258–61
- Setter SM, Corbett CF, Campbell RK, et al. Insulin aspart: a new rapid- acting insulin analog. Ann Pharmacother 2000: 34(12): 1423–31
- Home PD, Barriocanal L, Lindholm A. Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in healthy volunteers. Eur J Clin Pharmacol 1999; 55(3): 199–203
- Chapman TM, Noble S, Goa KL. Insulin aspart: a review of its use in the management of type 1 and 2 diabetes mellitus. Drugs 2002; 62(13): 1945–81
- Levien TL, Baker DE, White JR Jr, et al. Insulin glargine: a new basal insulin. Ann Pharmcother 2002; 36(6): 1019–27
- Yki-Jarvinen H, Dressier A, Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care 2000; 23(8): 1130–6
- Rosenstock J, Riddle M, Dailey G, et al. Treatment to target: feasibility of achieving control with the addition of basal bedtime insulin glargine (Lantus) or NPH insulin in insulin-naive patients with type 2 diabetes on oral agents. HOE901/4002 Study Group. (Abstr) Diabetes 2001; 50(Supp1 2): A129
- Vague P, Selam JL, Skeie S, et al. Insulin detemir is associated with a more predictable glycemic control and lower risk of hypoglycemia compared to NPH insulin in subjects with type 1 diabetes. (Abstr) Diabetes 2002; 51 (Supp1 23): A116
- Jacobson LV, Popescu G, Plum A. Pharmacokinetics of insulin detemir in patients with renal or hepatic impairment. (Abstr) Diabetes 2002; 51(Supp1 23): A102
- Pieber TR, Plank J, Goerzer E, et al. Duration of action, pharmacodynamic profile and between-subject variability of insulin detemir in subjects with type 1 diabetes. (Abstr) Diabetes 2002; 51(Supp1 23): A214